Strides Pharma’s arm gets USFDA’s approval for Lidocaine Ointment

13 Dec 2018 Evaluate

Strides Pharma Science’s step-down wholly owned subsidiary, Strides Pharma Global Pte., Singapore, has received approval for Lidocaine Ointment USP 5% from the United States Food & Drug Administration (USFDA). Lidocaine Ointment is a generic version of Xylocaine Ointment of AstraZeneca Pharmaceuticals LP.

According to IQVIA MAT data, the US market for Lidocaine Ointment USP 5% is approximately $50 million. The product will be marketed by Strides Pharma Inc. in the US Market and will be launched immediately. The company has 80 cumulative ANDA filings with USFDA of which 54 ANDAs have been approved as of date and 26 are pending approval.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

878.65 -7.00 (-0.79%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×